{"id":3889,"date":"2021-08-14T14:19:01","date_gmt":"2021-08-14T14:19:01","guid":{"rendered":"https:\/\/dreambody.clinic\/?p=3889"},"modified":"2024-04-01T01:36:16","modified_gmt":"2024-04-01T01:36:16","slug":"could-mesenchymal-stem-cells-improve-the-outcome-of-ards-in-severe-covid-19-cases","status":"publish","type":"post","link":"https:\/\/dreambody.clinic\/demo\/could-mesenchymal-stem-cells-improve-the-outcome-of-ards-in-severe-covid-19-cases\/","title":{"rendered":"Could Mesenchymal Stem Cells improve the outcome of ARDS in severe COVID-19 Cases?"},"content":{"rendered":"\n

The following information was written by Dr. Liji Thomas, MD about, Could Mesenchymal Stem Cells improve the outcomes of ARDS<\/a> in Severe COVID-19 Cases?<\/p>\n\n\n\n

The 2019 coronavirus disease (COVID-19) pandemic has been associated with hundreds of millions of hospitalizations and more than 3.2 million deaths since it first emerged in late 2019. While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily causes asymptomatic or mild disease, in approximately 15% of cases, patients become moderately or severely ill.<\/p>\n\n\n\n

A recent study, published in Stem Cells Translational Medicine, explores the safety and efficacy of stem cells, which have been touted as the panacea for a wide range of diseases, ranging from chronic degenerative diseases to cancer.<\/p>\n\n\n\n

The severity of COVID-19 in some patients appears to be due to a hyperinflammatory state resulting from a deregulated immune response. This is characterized by a storm of cytokines and immunologically mediated clots. A distressing and often fatal complication of critical COVID-19 is acute respiratory distress syndrome (ARDS), often associated with multiorgan dysfunction.<\/p>\n\n\n\n

Therapies are now needed to reduce the severity of inflammation, which can shorten the vicious cycle that shortens the survival of these patients. Corticosteroids have been shown to have significant use under specific conditions.<\/p>\n\n\n\n

It is argued that the use of stem cells in this scenario is of potential benefit in modulating immune responses in patients with severe COVID-19. Researchers in this study obtained umbilical cord mesenchymal stem cells (UC-MSC), which can proliferate rapidly for clinical use and have been reported to be safe in other conditions.<\/p>\n\n\n\n

These stem cells are not subject to ordinary host-graft incompatibility conditions and have been used in various autoimmune and inflammatory diseases. Approval has been granted by the U.S. Food and Drug Administration. For the use of UC-MSC for type 1 diabetes and Alzheimer’s disease<\/a>.<\/p>\n\n\n\n

Objectives and findings of the study<\/h2>\n\n\n\n

Some studies have shown good results in patients with COVID-19 pneumonia who were treated with MSC who do not express the angiotensin-converting enzyme 2 (ACE2) from the host cell molecule that serves as the virus receptor. This stimulated current research on the safety and efficacy of UC-MSC as a therapy for ARDS in patients with COVID-19.<\/p>\n\n\n\n

Conducted as a blinded randomised controlled trial, it was designed as a phase 1\/2a trial in 24 patients. First, it was observed that the use of these stem cells was safe. While more than 90% of patients in the treatment group survived 28 days from the last dose, only 42% in the control group did.<\/p>\n\n\n\n

Possible explanations<\/h2>\n\n\n\n

The key effects of stem cell treatment are to reduce the levels of inflammatory mediators such as interferon (IFN)-\u03b3, interleukin (IL)-6, and tumor necrotic factor (TNF)-\u03b1, which play a central role in the COVID-19 cytokine storm. Simultaneously, they reduce levels of granulocyte-monocyte colony-stimulating factor (GM-CSF), the main activator of the process by which monocytes are activated to become proinflammatory M1 macrophages. By doing so, they can shift the balance towards M2 macrophages that are activated by another route.<\/p>\n\n\n\n

Levels of PDGF-BB (a type of platelet-derived growth factor with two B subunits), which powerfully stimulates cells of mesenchymal origin, were also reduced. This mediator improves the activation of mesenchymal cells, stimulates the proliferation and migration of smooth muscle cells of the airways, increases the production of cytokines in pulmonary fibroblasts and activates pain-sensitive neurons.<\/p>\n\n\n\n

Therefore, a reduction in PDGF-BB levels could mean that MSC therapy accelerates the tissue repair process, thus accelerating recovery in the lungs, reducing the need for increased PDGF-BB secretion.<\/p>\n\n\n\n

Acute Respiratory Distress Syndrome ARDS Stem Cell Treatment<\/h1>\n\n\n\n

Acute Respiratory Distress Syndrome ARDS <\/a>Stem Cell Treatment is a stem cell therapy done with an 200 million stem cell IV followed by 4 sessions of 25 million nebulized stem cells.\u00a0 ARDS is one of those diseases that doctors currently can only manage the symptoms after lung failure. Mesenchymal Stem Cells flip this paradigm as they have now been found to treat ARDS with great success. When Mesenchymal Stem Cells (MSCs) are administered via IV they go directly to the lungs first. This is called the first pass and a great thing for ARDS as the majority of the stem cells (approximately 80%) never get past the lungs and heart. The stem cells are attracted to inflammation and the lungs are full of it. They get to work by guiding the removal of fibrosis (scarring) and then guiding the cellular repair. ARDS typically leaves patients with severely damaged lungs and no way to repair and regenerate. The MSCs are able to help you get your breath back.<\/p>\n\n\n\n

To get started please fill out our intake form and then we will call for a free consultation \u2013 INTAKE FORM<\/a><\/p>\n\n\n\n

Intranasal Stem Cell Application Study<\/strong><\/h3>\n\n\n\n

https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0014488614001964<\/a><\/p>\n\n\n\n

Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of lung damage. This study shows that intranasal stem cell application helps heal the lungs and brain. We prefer to use a nebulized approach for intranasal application as more stem cells are able to get to the mucus membrane and pass to the blood stream to go straight to the brain. <\/p>\n\n\n\n

TREATMENT PROTOCOL<\/h2>\n\n\n\n